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A B S T R A C T
Background
Assessment of events by adjudication committees (ACs) is recommended in multicentre randomised controlled trials (RCTs). However,
its usefulness has been questioned.
Objectives
The aim of this systematic review was to compare 1) treatment effect estimates of subjective clinical events assessed by onsite assessors
versus by AC, and 2) treatment effect estimates according to the blinding status of the onsite assessor as well as the process used to
select events to adjudicate.
Search methods
We searched Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, EMBASE, PsycINFO, CINAHL and Google
Scholar (25 August 2015 as the last updated search date), using a combination of terms to retrieve RCTs with commonly used terms
to describe ACs.
Selection criteria
We included all reports of RCTs and the published RCTs included in reviews and meta-analyses that reported the same subjective
outcome event assessed by both an onsite assessor and an AC.
Data collection and analysis
We extracted the odds ratio (OR) from onsite assessment and the corresponding OR from AC assessment and calculated the ratio
of the odds ratios (ROR). A ratio of odds ratios < 1 indicated that onsite assessors generated larger effect estimates in favour of the
experimental treatment than ACs.
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Main results
Data from 47 RCTs (275,078 patients) were used in the meta-analysis. We excluded 11 RCTs because of incomplete outcome data to
calculate the OR for onsite and AC assessments. On average, there was no difference in treatment effect estimates from onsite assessors
and AC (combined ROR: 1.00, 95% confidence interval (CI) 0.97 to 1.04; I2 = 0%, 47 RCTs). The combined ROR was 1.00 (95%
CI 0.96 to 1.04; I2 = 0%, 35 RCTs) when onsite assessors were blinded; 0.76 (95% CI 0.48 to 1.12, I2 = 0%, two RCTs) when AC
assessed events identified independently from unblinded onsite assessors; and 1.11 (95% CI 0.96 to 1.27, I2 = 0%, 10 RCTs) when
AC assessed events identified by unblinded onsite assessors. However, there was a statistically significant interaction between these
subgroups (P = 0.03)
Authors’ conclusions
On average, treatment effect estimates for subjective outcome events assessed by onsite assessors did not differ from those assessed by
ACs. Results of subgroup analysis showed an interaction according to the blinded status of onsite assessors and the process used to
submit data to AC. These results suggest that the use of ACs might be most important when onsite assessors are not blinded and the
risk of misclassification is high. Furthermore, research is needed to explore the impact of the different procedures used to select events
to adjudicate.
P L A I N L A N G U A G E S U M M A R Y
Comparison of central adjudication of outcomes and onsite outcome assessment on treatment effect estimates
It is widely recommended that multicentre randomised controlled trials (RCTs) should have a central process for assessing whether or
not a patient has had an event, rather than relying solely on the outcomes reported by assessors at the relevant site where the decision
might be subjective. These Adjudication Committees (ACs) are commonly used, especially in large trials. For example, the US Food
and Drug Administration (FDA) and the European Medicine Agency (EMA) recommend assessment of events by such committees to
harmonise and standardise outcome assessment across a trial. However, there is a need for evidence to justify the use of ACs and to
decide on how central adjudication of clinical events should be conducted. This is the first large meta-analysis across medical areas to
evaluate the impact of central adjudication on the estimates for treatment effect produced by RCTs. We investigated whether using the
event data from ACs produced different treatment effect estimates than the data from onsite for subjective outcomes in RCTs.
We defined an AC as a committee of clinical experts in a specific medical area that seeks to harmonise and standardise the outcome
assessment; whereas onsite assessors would be investigators, research nurses, data collectors, or patients themselves doing an onsite
evaluation of the occurrence of the outcome during the RCT. Onsite assessors may, or may not, be blinded to the treatment assigned.
We included all reports of RCTs and meta-analyses of published RCTs that reported the same subjective binary clinical event outcome
assessed by both an onsite assessor and an AC.
We combined the findings of 47 RCTs (275,078 patients) in our systematic review and meta-analysis in order to see if there is a
difference between the results from ACs and from onsite assessment. Our results showed that treatment effect estimates of subjective
clinical events did not differ, on average, from those assessed by ACs. When we divided the data into whether or not the onsite assessors
knew the patient’s allocated treatment in the RCT and the various ways of submitting data to ACs, we found that there might be
important differences between onsite assessment and ACs depending on which methods are used. Our findings, which are up to date
as of August 2015, raise important uncertainty about whether ACs are being used appropriately across all RCTs.
B A C K G R O U N D
An adjudication committee (AC) consists of a group of clinical ex-
perts in a specific medical area who validate the assessment of out-
comes in a randomised controlled trial (RCT). Central adjudica-
tion of clinical events is recommended and commonly used in large
multicentre RCTs (Stuck 2014). For example, the US Food and
Drug Administration (FDA) and the European Medicine Agency
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(EMA) recommend assessment of events by ACs to harmonise and
standardise outcome assessment. ACs are usually blinded to the as-
signed treatment, regardless of whether the trial itself is conducted
in a blinded manner. Such committees are considered valuable
when outcomes are subjective and when the intervention is not
delivered in a blinded fashion (Bellamy 1997), and ACs are used
to reduce bias and to ensure more precise classification of events
(Granger 2008).
Detection bias, which is also called ascertainment bias or observer
bias, might be expected with onsite assessment, mainly due to the
knowledge of the allocated interventions by the assessor (Higgins
2011). This implies, especially for subjective binary outcomes, that
there is a high risk of a biased effect estimates in RCTs whichmight
exaggerate the effect estimates (Hróbjartsson 2012). Therefore, an
AC might be a useful way to address such bias.
Description of the problem or issue
The importance of ACs has been advocated in some studies and
challenged in others. Some studies have shown that the classifica-
tion of events could change after outcome assessment by an AC
(Naslund 1999; Mahaffey 2001b; O’Connor 2005). In contrast,
other studies have shown that adjudicated data usually match well
with onsite outcome assessment (Kirwan 2007; Granger 2008;
Pogue 2009; Hata 2013).
Description of the methods being investigated
We investigated the impact of the use of an AC on treatment effect
estimates in RCTs. An AC is defined as a committee of clinical
experts in a specific medical area that harmonises and standardises
the outcome assessment. The onsite assessors represent investiga-
tors, research nurses, data collectors, or patients themselves doing
an onsite evaluation of the occurrence of the outcome during the
RCT. Onsite assessors may, or may not, be blinded to the treat-
ment assigned.
How these methods might work
The AC aims to increase the reliability of assessing outcomes by a
more accurate assessment of events, discarding events that are po-
tentially not valid and minimising bias (Boutron 2006; Boutron
2007; Dechartres 2009; Vannabouathong 2012). Hence, an AC
would provide a systematic, unbiased, and independent assess-
ment of outcomes by using a set of predefined criteria developed
before the initiation of the RCT. Adjudication of outcomes should
theoretically minimise bias through a blinded outcome assessment
(without knowledge of the patient’s allocated treatment) and re-
duce the variance that would exist between different site inves-
tigators through a standardised assessment with clearly defined
endpoint definitions (Vannabouathong 2011). The central assess-
ment carried out by the AC may be more accurate because it is
performed by an independent group of trained clinicians with
substantial expertise in the field, who are not otherwise involved
in the RCT and who are blinded to the treatment allocation as
well as to other factors (such as who is responsible for the care of
the patient). In contrast, endpoint assessment performed by onsite
assessors may be affected by conscious or unconscious detection
bias, especially in trials that do not use placebo controls and have
subjective outcomes (Hróbjartsson 2012).
Researchers have outlined the importance of ACs, showing differ-
ences in classification of clinical events between onsite assessment
and AC assessment (Mahaffey 2001a; Mahaffey 2002; O’Connor
2005; Mahaffey 2011; Eriksson 2012; Winston 2012). These dif-
ferences may be the result of bias in the original classification but
they might be due to other causes which might not lead to differ-
ences in the treatment effect estimates.
Why it is important to do this review
The use of ACs in RCTs is frequent, particularly in some medical
areas such as cardiology. For example, in a sample of 969 trials of
venous thromboembolism, 69% reported the use of an AC (Stuck
2014). In addition, in a sample of RCTs published in high-impact
journals, the use of AC was reported in 33% of the 314 trials,
ranging from 9% of 34 RCTs in infectious diseases to 81% of 75
RCTs in cardiology (Dechartres 2009).
The adjudication process can be costly because it involves iden-
tifying the cases to be adjudicated, collecting all the data to be
adjudicated (case report forms, biological tests, radiography and
other complementary tests, etc), anonymising and masking the
data, identifying and inviting the adjudication members, training
adjudication members, adjudicating the data, organising regular
consensus meetings, and so forth.
Adjudication outcome assessment is highly recommended for
studies that include subjective outcomes when blinding is not pos-
sible, and there is clear evidence that unblinded outcome assess-
ment of subjective outcomes will overestimate treatment effect es-
timates (Wood 2008; Hróbjartsson 2012; Savovi 2012).
To our knowledge, no comprehensive systematic review across
medical areas has been published on this topic.
O B J E C T I V E S
We sought to assess the impact of adjudication committee (ACs)
versus onsite outcome assessment on treatment effect estimates for
subjective outcomes in randomised controlled trials (RCTs).
M E T H O D S
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Criteria for considering studies for this review
Types of studies
We included all reports of RCTs and any published RCTs included
in reviews and meta-analyses (using these as a source of data on
the individual studies) that reported the same subjective binary
clinical event outcome assessed by both an onsite assessor and an
AC. So, to be eligible, a study had to provide data to calculate the
odds ratio (OR) for onsite assessment and for AC separately.
We excluded RCTs comparing AC assessment with administrative
data (e.g., death certificates) or with outcome assessment by a lo-
cal outcome committee. We also excluded RCTs using the same
treatment in the two allocated groups. Furthermore, reports de-
scribing a specific complementary examination such as phlebogra-
phy (evaluated only by imaging) were excluded. We also excluded
RCTs in which it is unclear which intervention is “experimental”
and which is “control” because such RCTs did not allow us to
determine the direction of any bias on the effect estimate.
We did not place any restrictions on the number of centres in-
cluded in the RCTs selected for the review. Single- andmulticentre
trials were eligible for inclusion.
Types of data
Eligible studies reported a subjective binary clinical event outcome.
An outcome was considered “subjective” if it was based on an ob-
server exercising judgment while assessing an event or state and
could consequently be influenced by the assessor’s knowledge of
the allocated treatment (Moustgaard 2014). Objective outcomes
were those determined without exercising judgment. We selected
trials with subjective clinical events because there is evidence that
blinding of outcome assessors is particularly important for sub-
jective outcomes, but not for objective outcomes (Wood 2008;
Hróbjartsson 2012; Savovi 2012).
Types of methods
All eligible RCTs directly compared central versus onsite assess-
ment for the same outcome.
Types of outcome measures
Primary outcomes
Our primary outcome was the impact of the AC on the treatment
effect estimate for a subjective binary clinical outcome in the rel-
evant RCT, compared to onsite assessment.
Two review authors (LAND, AY) independently selected one out-
come from the article reporting each included RCT. This outcome
will have been assessed by both an onsite assessor and an AC, and
the data needed to have been provided for each treatment group.
The decision to label an outcome as “subjective” was made by two
trained clinical epidemiologists (LAND, AY). Disagreements were
resolved by discussion with a third review author (IB). We only re-
ferred to the adjudication of outcomes, not to the adjudication of
other data in the trial (e.g., baseline characteristics). If the primary
outcome was a composite of objective and subjective outcomes,
we selected at least one subjective outcome component that had
been assessed by both an onsite assessor and an AC.
If several outcomes in a RCT were assessed by an onsite assessor
and an AC, we selected only one outcome. For this purpose, we
first selected all efficacy outcomes when available. If several effi-
cacy outcomes were available, we selected the efficacy outcome(s)
reported as primary outcome(s) of the RCT (i.e., as clearly stated
in the RCT article, described in the study objectives, or used for
the sample size calculation). If none or several were reported as
primary outcome(s), we selected the most clinically relevant out-
comes, and among them the outcome with the most events. We
used the same selection process if the outcomes assessed by both
an onsite assessor and an AC were only safety outcomes. If several
time points were reported for an outcome, we selected the first
time point after the end of treatment.
Secondary outcomes
There were no secondary outcomes for this review because our
aim was to evaluate the impact of AC versus onsite assessment on
the treatment effect estimates.
Search methods for identification of studies
Electronic searches
We searched a variety of standard databases (Cochrane Central
Register of Controlled Trials (CENTRAL), PubMed, EMBASE,
PsycINFO, CINAHL) up to 18 March 2014 and updated our
search most recently in August 2015 using the search strategies
listed in Appendix 1. We also searched the full-text database
(Google Scholar) with commonly used terms including adjudica-
tion committee, central adjudication, endpoint committee, clini-
cal event committee, outcome committee, critical event commit-
tee.
Searching other resources
We checked the references of included studies to identify addi-
tional relevant reports (Horsley 2011).
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Data collection and analysis
If anyRCTs identified in our initial search only reported the results
of clinical events assessed by an AC, we sought the authors’ email
addresses and contacted them to ask whether they had collected
onsite outcome data and whether they could provide these data.
Selection of studies
One review author (LAND) screened all titles, abstracts and text
fragments retrieved from the databases. The information selected
was reviewed by a second review author (CB) to confirm relevance
to the review. The review authors obtained the full-text study re-
ports relating to every potentially eligible record. If the selected
report was an ancillary analysis of the RCT comparing onsite as-
sessor and AC assessments, the primary report of the RCT was
also retrieved.
When the selected report was a report of a meta-analysis pooling
data of individual RCTs in which the treatment effect estimates
from the AC and the onsite assessor was compared, the primary
reports of the included RCTs were systematically searched for and
evaluated. If primary reports of these RCTS were not available,
we collected data from the meta-analysis and reported the total
number of events in each treatment group resulting from the onsite
assessor and AC assessment for each RCT. However, we excluded
the RCTs in the meta-analysis report if the meta-analysis reported
only combined effect estimates, and did not provide the effect
estimates for each RCT separately.
Data extraction and management
We used a pre-tested data extraction form (Appendix 2) to collect
general characteristics and outcome data of the eligible reports.
Two review authors (LAND, CB) extracted the following data
independently and disagreements were resolved by discussion.
General characteristics of the RCT: medical speciality, funding
source, experimental intervention, comparator. We considered
that onsite assessors were blinded if the study was reported as a
double-blind study, a similar placebo procedure was used, a dou-
ble-dummy procedure was used, or a specific methodwas reported
to blind the onsite assessor when patients and care providers were
not blinded.
Data on the functioning of the AC: blinding status of the AC in
terms of allocated treatment and to the onsite assessment, training
and independence of AC members, and information provided to
the AC. We extracted the method for selecting cases to adjudicate
(i.e., whether this used events identified by the onsite assessor,
computer algorithms to identify suspected events, adjudication of
all patients randomised and the assessment of all deaths in the
context of determining a specific cause of death).
Outcome data: total number of events in each randomised group
resulting fromonsite-assessor andAC assessments.When possible,
we extracted paired patient-level data for onsite-assessor and AC
assessment and constructed a 2×2 table (event/no event x onsite/
AC) for the experimental group and a corresponding table for the
control group. ForRCTswithmore than twogroups, we combined
the results for the experimental groups. We estimated treatment
effects as odds ratios (ORs). Outcome events were recoded in all
RCTs such that an OR < 1 indicates benefit from the experimental
treatment.
Assessment of risk of bias in included studies
A possible risk of bias for the comparison of onsite assessment ver-
sus ACs is linked to the method used to select cases to adjudicate.
This selection could be biased if it is not blinded to the allocated
treatment, for example if the events to be adjudicated were iden-
tified by the unblinded onsite assessor. To investigate this, we col-
lected the method for selecting cases to adjudicate. These meth-
ods were classified as “events identified independently of onsite-
assessor assessment” if 1) events to be adjudicated were identified
with a computer algorithms, 2) all patients randomised were ad-
judicated, or 3) all deaths were adjudicated when the outcome
of interest was a specific cause of death. Selection methods were
considered as low risk of bias if the onsite assessor was blinded or
if events were identified independently of onsite-assessor assess-
ment. If events were identified by unblinded onsite-assessors, we
considered this to have a high risk of bias. We used unclear risk
of bias if the methods of selection and blinded status of onsite
assessors were not clear.
Measures of the effect of the methods
We summarised the effects by comparing the effect estimates for
the same clinical event outcome in each RCT that were calculated
with the outcome data from the onsite assessor versus the same
analysis using outcome data from the AC. For each RCT, we cal-
culated the ratio of ORs (ROR) as the OR from onsite assessors
relative to the corresponding OR from the AC (ROR = OROnsite/
OR AC). An ROR < 1 indicated that onsite assessors generated
larger effect estimates in favour of the experimental treatment than
ACs.
Unit of analysis issues
Because the onsite assessor and the AC classified outcome events
for the same study population, the two corresponding estimates
were correlated. The standard error of the logROR was calculated
as the square root of the sum of the variance of the logOR for
AC and onsite assessment. It was our intention to use the delta
method so that the standard error of the logRORtook into account
the correlation between onsite and AC assessment (Bagos 2012;
Hróbjartsson 2012), butwewere unable to do this because the data
required to estimate the covariance of the two correlated logORs
were not available.
5Comparison of central adjudication of outcomes and onsite outcome assessment on treatment effect estimates (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Dealing with missing data
When data were incomplete (e.g., authors reported the total num-
ber of events resulting from the onsite-assessor and AC assess-
ment but did not provide the data separately for each randomised
group), we wrote to the corresponding author to ask for the results
by group.
Assessment of heterogeneity
Heterogeneity was assessed by the I2 statistic and the between-
trial variance τ ². I2 was the proportion of total variation between
the studies attributable to differences between RCTs rather than
to sampling error (chance), with values < 30% representing low
heterogeneity, ≤ 60% moderate heterogeneity, and > 60% high
heterogeneity.
Assessment of reporting biases
To minimise reporting bias, for all RCTs identified in our initial
search which were excluded because they only reported the results
of clinical events assessed by an AC, we contacted the correspond-
ing author to request the data for onsite assessors. We explored the
impact of these data on the results in a sensitivity analysis.
We did not intend to perform any other specific assessment of
reporting bias because the statistical tools commonly used to assess
reporting bias and related small-study effects in meta-analysis (in
particular the funnel plot) have not been transposed or extended
to meta-epidemiological studies.
Data synthesis
We pooled the individual RORs using a DerSimonian and Laird
random-effects meta-analysis (DerSimonian 1986), and reported
the results in a forest plot with 95%confidence intervals (CIs). The
decision topool theRORswas based on the assessment of statistical
heterogeneity and methodological diversity. If data combination
was deemed inappropriate, we presented the results of individual
studies in a forest plot (without a meta-analysis) and discussed
them.We considered the point estimate of the ROR significant at
P < 0.05 if the 95% CI did not include the value 1.
Subgroup analysis and investigation of heterogeneity
We tested the interactionbetween theRORand the blinding status
of onsite assessors and ACs as well as the method used to select
cases to adjudicate (events identified by or independent of onsite-
assessor assessment).
Sensitivity analysis
We conducted a sensitivity analysis to explore the impact of unre-
ported data on our results.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
The screening process is described in Figure 1.We examined 1210
full-text articles based on 7855 hits in standard databases and 1893
hits in the full-text database. After reading the full-text articles,
we selected 25 reports of RCTs and four reports of meta-analyses
which had included 21RCTs. Two reports of RCTswere identified
from the personal collections of the authors. Of the 874 full-
text articles reporting only results for the AC, we obtained an e-
mail address for corresponding authors of 496 trials; 106 authors
responded and we obtained the data for 10 RCTs. Finally, we
included 47 RCTs (with a total of 275,078 patients) in our meta-
analysis.
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Figure 1.
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Included studies
Table 1 shows the baseline characteristics of the 47 RCTs included
in themeta-analysis. Themedian sample size was 3449 [interquar-
tile range 1506 to 10,000], 83% (n = 39) of RCTs were in the
field of cardiology, 89% (n = 42) weremulticentre RCTs, and 94%
were sponsored completely or partially by industry.
The outcomes selected for assessment were mainly the RCT’s pri-
mary outcomes (n = 39, 83%). Many RCTs (n = 32; 68%) studied
a composite outcome.Most of these composite outcomes included
subjective outcomes only (n = 35; 75%), but 25% (n = 12) were
a composite of subjective and objective outcomes. Details related
to the AC are in Table 2. For 40 RCTs (85%), ACs were reported
as blinded to the treatment allocated. The AC evaluated mainly
suspected cases (failure events) identified by the onsite assessor (n
= 37; 79%). For 35 RCTs (75%), the onsite assessor was blinded
to the treatment allocated.
Excluded studies
We excluded 11 studies because they did not provide the neces-
sary data to calculate the OR for onsite assessment and for AC
separately (Characteristics of excluded studies). We contacted the
corresponding authors of these 11 studies but did not receive any
responses after at least two reminders.
Risk of bias in included studies
A possible risk of bias is linked to the method for selecting cases
to adjudicate, especially when the relevant events are identified by
the unblinded onsite assessor.
Overall, 35 RCTs (75%) reported using blinded onsite assessors.
Among the 12 RCTs with unblinded onsite assessors, events sub-
mitted to ACs were identified by the unblinded onsite assessors in
10 RCTs. In the two other unblinded RCTs, events submitted to
ACs were identified independently of the onsite assessors.
Effect of methods
Treatment effect estimates from the onsite assessment and the ACs
are shown in Figure 2 for the 47 included RCTs. We found no
difference, on average, in treatment effect estimates between onsite
assessment and ACs. The combined RORwas 1.00 (95% CI 0.97
to 1.04), with no heterogeneity (I2 = 0%, τ ² = 0%) (n = 47 RCTs).
Furthermore, we found no evidence of interaction by blinding
status of onsite assessors ROR = 1.00, 95% CI 0.96 to 1.04 with
blinded onsite assessors (n = 35 RCTs) and with unblinded onsite
assessors (ROR 1.08, 95% CI 0.94 to 1.23, 12 RCTs); P = 0.07
(Table 3).
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Figure 2. Impact of adjudication committee assessment on estimated intervention effects in randomised
clinical trials measured as ratio of odds ratios (odds ratio based on onsite outcome assessment divided by odds
ratio based on adjudication committee assessment)
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However, subgroup analysis showed a statistically significant in-
teraction by blinding status of onsite assessor and the process for
submitting data to the AC. The combined ROR was 1.00 (95%
CI 0.96 to 1.04, I2 = 0%, 35 RCTs) with blinded onsite assessors;
0.76 (95% CI 0.48 to 1.21, I2 = 0%, two RCTs) with AC-assessed
events identified independent of unblinded onsite assessors; and
1.11 (95% CI 0.96 to 1.27, I2 = 0%, 10 RCTs) with AC-assessed-
only events identified by unblinded onsite assessors ; P = 0.03
(Figure 2, Table 3).
D I S C U S S I O N
Summary of main results
We performed a meta-analysis of 47 randomised controlled trials
(RCTs) (275,078 patients) to compare treatment effect estimates
of subjective clinical events assessed by onsite assessors and byACs.
The combined ROR was 1.00 (95% CI 0.97 to 1.04). Results
of subgroup analyses showed an interaction by blinding status of
onsite assessors and the process used to submit data to ACs, with
an increase in the effect estimate for the experimental treatment
with onsite assessment compared to ACwhen the events were sub-
mitted by unblinded onsite assessors compared to when they were
submitted by blinded onsite assessors or submitted independently
of unblinded onsite assessors.
Overall completeness and applicability of
evidence
The included RCTs are mainly large multicentre trials in cardiol-
ogy. These results should be extrapolated to other medical areas
with caution, but the included RCTs are representative of trials
using ACs (Dechartres 2009; Stuck 2014).
Quality of the evidence
Our review has several strengths. First, our search strategy allowed
for identifying trials with no restriction on medical area. Second,
we identified a large sample of high-quality RCTs with a large
sample of patients in total. Third, our study featured low risk
of confounding because of the direct comparison of onsite and
AC assessment of the same outcome in the same study involving
the same patients. Finally, the large number of included studies
allowed us to perform a prespecified subgroup analysis related to
the blinding status of onsite assessors and the submission of data
to ACs.
Potential biases in the review process
Our review has some limitations. First, we cannot exclude a selec-
tive reporting bias, and investigators might be less prone to report
the results of both AC and onsite assessors if the results differed.
Furthermore, 11 RCTs (Characteristics of excluded studies) could
not be included in the meta-analysis because data were not avail-
able to compare the results for the randomised groups even though
we contacted the corresponding authors of these RCTs to request
the missing data. In contrast, we contacted authors reporting only
outcomes assessed by ACs and obtained estimates for the onsite
assessor for 10 RCTs. Second, the outcomes selected had variable
levels of subjectivity, with 25% concerning composite outcomes
including both subjective and objective outcomes (such as death).
Third, we identified only two RCTs that had used unblinded on-
site assessment, a blinded AC and an unbiased method for select-
ing cases to be adjudicated. Finally, we could not incorporate the
correlation between effect estimates for ACs and onsite assessors
because the data required to estimate the covariance were not avail-
able.
Agreements and disagreements with other
studies or reviews
The largest previous study in this topic was published by Pogue
and colleagues (Pogue 2009). They selected 10 RCTs conducted at
the Population Health Research Institute in the field of cardiology.
They did not detect any effect of event adjudication on the treat-
ment effect estimates and raised the need to conduct more system-
atic analyses of the effect of the event adjudication in other trials
to determine if this process is worthwhile. Other researchers have
outlined the importance of ACs showing that misclassifications
between onsite-assessor and AC assessment can be frequent. How-
ever, these misclassifications may not be biased and might not lead
to differences in treatment effect estimates (Hata 2013, Kirwan
2007). Because establishing and running an AC is time and re-
source consuming, some argue that ACs should be implemented
only when the risk of misclassification is high (i.e., when onsite as-
sessors are not blinded and the outcomes are subjective) (Granger
2008, Dechartres 2009). Indeed, we have previously shown that
unblinded assessors of subjective clinical events generated sub-
stantially biased effect estimates in RCTs, exaggerating ORs by
36% (Hróbjartsson 2012). Prospective randomised, open, blinded
end-point (PROBE) studies are particularly recommended when
blinding of patients and care providers is not feasible (Hansson
1992, Boutron 2006, Boutron 2007). Nevertheless, of the 47 tri-
als we investigated, 35 (75%) had blinded onsite assessors, so the
risk of biased misclassification was low. Similarly, previous work
has shown that most ACs were implemented when onsite assessors
are blinded or the outcome is objective (Dechartres 2009; Stuck
2014). This situation implies excessive cost and research waste
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(Ioannidis 2014, Al-Shahi Salman 2014) .
In contrast, ACs would be important when onsite assessors are
not blinded. We explored the impact of the blinding status of
onsite assessors and did not detect an effect of AC assessment when
onsite assessors were not blinded, with an estimated ROR of 1.08
(95% CI 0.94 to 1.23). These results could be related to the use
of inadequate methods to capture suspected events, and biased
submission of events by unblinded onsite assessors could result in
a biased treatment effect estimated from ACs.
The question of the mode of data submission to the AC is im-
portant. In 79% of the RCTs included in our meta-analysis, the
method used to select cases to adjudicate was suspected events
identified by the onsite assessor. Consequently, events that the on-
site assessors had missed would not have been adjudicated. There-
fore, when onsite assessors are not blinded, the estimated treat-
ment effect by the AC could be biased because the ACwill evaluate
a biased sample of events identified by unblinded onsite assessors.
The use of an AC could provide a false security because it does not
control for the differential misclassification from onsite assessors.
This issue was raised for the RECORD study and prompted the
US FDA to modify the method for selecting cases to be adjudi-
cated (Psaty 2010; Lopes 2013), although the “readjudication” of
RECORD data also raised some concerns (Nissen 2013).
A U T H O R S ’ C O N C L U S I O N S
Implication for methodological research
Further research is needed to explore the impact of the different
procedures used to select events to adjudicate.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
ACTIVE-W 2006
Methods RCT comparing clopidogrel plus aspirin versus oral anticoagulation therapy for atrial
fibrillation for prevention of vascular events
Data 6706 patients were randomised (3371 in clopidogrel group/3335 in control group)
Comparisons Onsite assessment (local investigator non blinded) versus assessment by an AC blinded
to allocated treatment
Outcomes The outcomes selected were stroke or non-central nervous systematic embolus or my-
ocardial infarction or vascular death
Notes The study was identified because it was included in a pooled analysis of 10 RCTs (Pogue
2009). Data related to the number of events in each treatment group resulting from
onsite-assessor and AC assessments were extracted from this meta-analysis on the primary
outcomes of the included studies
Risk of bias
Item Authors’ judgement Description
Method for selecting cases to adjudicate? Yes All suspect events adjudicated were identi-
fied by onsite assessor who was not blinded
to allocated treatment
Bauersachs 2010
Methods RCT comparing rivaroxaban versus enoxaparin in patients with acute and symptomatic
deep-vein thrombosis
Data 3449 patients were randomised (1731/1718, respectively in each treatment group)
Comparisons Onsite assessment (local investigator non blinded) versus assessment by an AC blinded
to allocated treatment
Outcomes The outcome selected was recurrent venous thromboembolism. This was the study’s
primary outcome
Notes Data related to the number of events in each treatment group resulting from onsite-
assessment were obtained directly from the study authors
Risk of bias
Item Authors’ judgement Description
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Bauersachs 2010 (Continued)
Method for selecting cases to adjudicate? Yes All suspect events adjudicated were identi-
fied by onsite assessor who was not blinded
to allocated treatment
Bennet-Guerrero 2010
Methods RCT evaluating effect of an Implantable Gentamicin-Collagen Sponge versus no inter-
vention (control) on sternal wound infections following cardiac surgery
Data 1502 patients were randomised (753/749 respectively in each treatment group)
Comparisons Onsite assessment (local investigator non blinded) versus assessment by an AC blinded
to allocated treatment
Outcomes The selected outcome was the incidence of sterna wound infection. This was the study’s
primary outcome
Notes
Risk of bias
Item Authors’ judgement Description
Method for selecting cases to adjudicate? Yes All suspect events adjudicated were identi-
fied by onsite assessor who was not blinded
to allocated treatment
BIP 2000
Methods RCT comparing bezafibrate versus placebo in patients with coronary artery disease
Data 3122 patients were randomised (1542/1558, respectively in each treatment group), 32
patients were excluded from analysis because they never started the study medication
Comparisons Onsite assessment (local investigator blinded) versus assessment by an AC blinded to
allocated treatment
Outcomes The outcome selected was fatal or non fatal myocardial infarction or sudden death. The
study’s primary outcome was time to one these events
Notes Data related to the number of events in each treatment group resulting from onsite-
assessment were obtained directly from the study authors
Risk of bias
Item Authors’ judgement Description
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BIP 2000 (Continued)
Method for selecting cases to adjudicate? No All suspect events adjudicated were identi-
fied by onsite assessor who was blinded to
allocated treatment
Bolland 2013
Methods RCT assessing calcium supplementation in healthy postmenopausal women
Data 1471 patients were randomised (732/739 respectively in each treatment group)
Comparisons Onsite assessment (patient self-reported outcomes) versus assessment by an AC blinded
to allocated treatment
Outcomes The outcome selected was stroke, which was not the study’s primary outcome
Notes
Risk of bias
Item Authors’ judgement Description
Method for selecting cases to adjudicate? No Events adjudicated were identified by on-
site assessor who was blinded to allocated
treatment
Bresalier 2005
Methods RCT comparing rofecoxib versus placebo for the prevention of colorectal adenoma
Data A total of 3260 patients were screened for the study, of whom 2586 were deemed to be
eligible (1287/1299 were randomised respectively in each treatment group)
Comparisons Onsite assessment (local investigator blinded) versus assessment by an AC blinded to
allocated treatment
Outcomes The outcome selected was the total number of thrombotic cardiovascular events
Notes
Risk of bias
Item Authors’ judgement Description
Method for selecting cases to adjudicate? No All suspect events adjudicated were identi-
fied by onsite assessor who was blinded to
allocated treatment
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Büller 2008
Methods RCT comparing rivaroxaban versus low molecular weight heparin in the treatment of
patients with acute symptomatic deep vein thrombosis
Data 543 patients were randomised (406/137, respectively in each treatment group)
Comparisons Onsite assessment (local investigator non blinded) versus assessment by an AC blinded
to allocated treatment
Outcomes The outcome selected was a composite outcome of symptomatic non fatal pulmonary
embolism events or symptomatic recurrent deep venous thrombosis events. This was the
study’s primary outcome
Notes Data related to the number of events in each treatment group resulting from onsite-
assessment were obtained directly from the study authors
Risk of bias
Item Authors’ judgement Description
Method for selecting cases to adjudicate? Yes All suspect events adjudicated were identi-
fied by onsite assessor who was not blinded
to allocated treatment
Büller 2012
Methods RCT comparing oral rivaroxaban versus enoxaparin for the treatment of symptomatic
pulmonary embolism
Data 4833 patients were randomised (2420/2413, respectively in each treatment group)
Comparisons Onsite assessment (local investigator non blinded) versus assessment by an AC blinded
to allocated treatment
Outcomes The outcome selected was recurrent venous thromboembolism. It was the study’s primary
outcome
Notes Data related to the number of events in each treatment group resulting from onsite-
assessment were obtained directly from the study authors
Risk of bias
Item Authors’ judgement Description
Method for selecting cases to adjudicate? Yes All suspect events adjudicated were identi-
fied by onsite assessor who was not blinded
to allocated treatment
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CHARM 2003
Methods RCT comparing candesartan versus placebo in patients with chronic heart failure and
preserved left-ventricular ejection fraction
Data 3025 patients were randomised (1514/1509, respectively in each treatment group), in-
cluding two patients who mistakenly received randomisation numbers but had no other
data recorded and never received study medication
Comparisons Onsite assessment (local investigator blinded) versus assessment by an AC blinded to
allocated treatment
Outcomes The outcome selectedwas admission to hospital for chronic heart disease or cardiovascular
death. The study’s primary outcome was cardiovascular death or admission to hospital
for chronic heart failure
Notes The study was identified because it was include in a review of six RCTs (Granger 2008)
. Data related to the number of events in each treatment group resulting from onsite-
assessor and AC assessments were extracted from this review
Risk of bias
Item Authors’ judgement Description
Method for selecting cases to adjudicate? No All suspect events adjudicated were identi-
fied by onsite assessor who was blinded to
allocated treatment
CREATE 2005
Methods RCT comparing reviparin versus placebo in patients with acute myocardial infarction
presenting with ST-segment elevation
Data 15,570 patients were randomised (7780/7790, respectively in each treatment group)
Comparisons Onsite assessment (local investigator blinded) versus assessment by an AC blinded to
allocated treatment
Outcomes The outcome selected was myocardial infarction or stroke at 7 days or death
Notes The study was identified because it was included in a pooled analysis of 10 RCTs (Pogue
2009). Data related to the number of events in each treatment group resulting from
onsite-assessor and AC assessments were extracted from this meta-analysis on the primary
outcomes of the included studies
Risk of bias
Item Authors’ judgement Description
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CREATE 2005 (Continued)
Method for selecting cases to adjudicate? No All events adjudicated were identified by
onsite assessor who was blinded to allocated
treatment
CURE 2001
Methods RCT comparing clopidogrel plus aspirin versus placebo in patients with acute coronary
syndromes without ST-segment elevation
Data 12,562 patients were randomised (6259/6303, respectively in each treatment group)
Comparisons Onsite assessment (local investigator blinded) versus assessment by an AC blinded to
allocated treatment
Outcomes The outcome selected was myocardial infarction, stroke or cardiovascular death
Notes The study was identified because it was included in a pooled analysis of 10 RCTs (Pogue
2009). Data related to the number of events in each treatment group resulting from
onsite-assessor and AC assessments were extracted from this meta-analysis on the primary
outcomes of the included studies
Risk of bias
Item Authors’ judgement Description
Method for selecting cases to adjudicate? No All suspect events adjudicated were identi-
fied by onsite assessor who was blinded to
allocated treatment
EPIC 1994
Methods RCT comparing c7E3 Fab bolus and infusion versus placebo in high-risk patients ongoing
coronary angioplasty
Data 2099 patients were randomised (1403/696, respectively in each treatment group)
Comparisons Onsite assessment (local investigator blinded) versus assessment by an AC blinded to
allocated treatment
Outcomes The outcome selected was non fatal myocardial infarction or death from any cause. This
was a prespecified composite of any of the following events in the first 30 days after
randomisation
Notes The study was identified because it was include in a review of six RCTs (Granger 2008)
. Data related to the number of events in each treatment group resulting from onsite-
assessor and AC assessments were extracted from this review
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EPIC 1994 (Continued)
Risk of bias
Item Authors’ judgement Description
Method for selecting cases to adjudicate? No All suspect events adjudicated were identi-
fied by onsite assessor who was blinded to
allocated treatment
Fiessinger 2005
Methods RCT comparing ximelagatran versus low molecular weight heparin and warfarin for the
treatment of deep vein thrombosis
Data 2528 patients were randomised (1258/1270, respectively in each treatment group)
Comparisons Onsite assessment (local investigator blinded) versus assessment by an AC blinded to
allocated treatment
Outcomes The outcome selected was recurrent venous thromboembolism. The primary composite
outcome was recurrent venous thromboembolism, bleeding, and mortality
Notes
Risk of bias
Item Authors’ judgement Description
Method for selecting cases to adjudicate? No All suspect events adjudicated were identi-
fied by onsite assessor who was blinded to
allocated treatment
Francis 2002
Methods RCT comparing ximelagatran versus warfarin for the prevention of thromboembolism
after total knee arthroplasty
Data 680 patients were randomised (348/332, respectively in each treatment group)
Comparisons Onsite assessment (local investigator blinded) versus assessment by an AC blinded to
allocated treatment
Outcomes The outcome selected was total thromboembolism. The study’s primary outcome was the
incidence of deep venous thrombosis (proximal or distal) or pulmonary embolism
Notes
Risk of bias
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Francis 2002 (Continued)
Item Authors’ judgement Description
Method for selecting cases to adjudicate? No All suspect events adjudicated were identi-
fied by onsite assessor who was blinded to
allocated treatment
Gulizia 2008
Methods RCT designed to test the non-inferiority of class IC antiarrhythmic drugs to amiodarone,
in patients paced for sinus node disease
Data 176 patients were enrolled: 70 patients were discharged on amiodarone, 75 patients were
discharged on class IC agents (38 on propafenone and 37 on flecainide), and 31 were
discharged on sotalol
Comparisons Onsite assessment (local investigator non blinded) versus assessment by an AC blinded
to allocated treatment
Outcomes The outcome selected was a composite outcome of death, permanent atrial tachyarrhyth-
mias, cardiovascular hospitalisation, atrial cardioversion or antiarrhythmic drug change.
This was the study’s primary outcome
Notes Data related to the number of events in each treatment group resulting from onsite-
assessment were obtained directly from the study authors
Risk of bias
Item Authors’ judgement Description
Method for selecting cases to adjudicate? Yes All suspect events adjudicated were identi-
fied by onsite assessor who was not blinded
to allocated treatment
GUSTO-IIb 1996
Methods RCT comparing recombinant hirudin versus heparin for the treatment of acute coronary
syndromes
Data 12,142 patients randomised (6069/6073, respectively in each treatment group. Patients
were stratified according to the presence of ST-segment elevation on the base-line elec-
trocardiogram (4131 patients) or its absence (8011 patients), with the latter characteristic
considered to indicate unstable angina or non-Q-wave myocardial infarction
Comparisons Onsite assessment (local investigator blinded) versus assessment by an AC blinded to
allocated treatment
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GUSTO-IIb 1996 (Continued)
Outcomes The outcome selected was a composite outcome of myocardial infarction or reinfarction
at 30 days or death from any cause. This was the study’s primary outcome
Notes The study was identified because it was included in a review of six RCTs (Granger 2008)
. Data related to the number of events in each treatment group resulting from onsite-
assessor and AC assessments were extracted from this review
Risk of bias
Item Authors’ judgement Description
Method for selecting cases to adjudicate? No All suspect events adjudicated were identi-
fied by onsite assessor who was blinded to
allocated treatment
Hata 2013
Methods RCT assessing the effects of the routine administration of an angiotensin- converting en-
zyme inhibitor-diuretic combination on serious vascular events in patients with diabetes,
irrespective of initial blood pressure levels or the use of other blood pressure lowering
drugs
Data 11,140 were randomised (5569/5571, respectively to perindopril-indapamide and to
placebo)
Comparisons Onsite assessment (local investigator blinded) versus assessment by an AC blinded to
allocated treatment
Outcomes The outcome selected was a composite outcome of major macro (non fatal myocardial
infarction, non fatal stroke and cardiovascular death) and microvascular events (new or
worsening nephropathy and retinopathy). This was the study’s primary outcome
Notes
Risk of bias
Item Authors’ judgement Description
Method for selecting cases to adjudicate? No All suspect events adjudicated were identi-
fied by onsite assessor who was blinded to
allocated treatment
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Hawkey 2007
Methods RCT comparing lumiracoxib versus nonsteroidal anti-inflammatory drugs (naproxen or
ibuprofen) in patients with osteoarthritis
Data 18,325 patients were randomised and 18,244 received at least 1 dose of study medication:
lumiracoxib (9117 patients), naproxen (4730 patients), oribuprofen (4397 patients)
Comparisons Onsite assessment (local investigator blinded) versus assessment by an AC blinded to
allocated treatment
Outcomes The outcome selectedwas all definite or probable ulcer complications. This was the study’s
primary outcome
Notes
Risk of bias
Item Authors’ judgement Description
Method for selecting cases to adjudicate? No All suspect events adjudicated were identi-
fied by onsite assessor who was blinded to
allocated treatment
Hochman 2006
Methods RCT comparing percutaneous coronary intervention plus thrombolytic therapy versus
thrombolytic therapy alone in patients who had total occlusion of the infarct-related
artery 3 to 28 days after myocardial infarction
Data 2166 patients were randomised (1082/1084, respectively in each treatment group)
Comparisons Onsite assessment (local investigator non blinded) versus assessment by an AC blinded
to allocated treatment
Outcomes The selected outcome was a composite outcome of reinfarction or heart failure or death
from any cause.This was the study’s primary outcome
Notes
Risk of bias
Item Authors’ judgement Description
Method for selecting cases to adjudicate? Yes All suspect events adjudicated were identi-
fied by onsite assessor who was not blinded
to allocated treatment
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HOPE 2000
Methods RCT comparing ramipril versus placebo to prevent cardiovascular events in high-risk
patients
Data 9297 patients randomised (4645/4652, respectively in each treatment group)
Comparisons Onsite assessment (local investigator blinded) versus assessment by an AC blinded to
allocated treatment
Outcomes The outcome selected was myocardial infarction, stroke or cardiovascular death
Notes The study was identified because it was included in a pooled analysis of 10 RCTs (Pogue
2009). Data related to the number of events in each treatment group resulting from
onsite-assessor and AC assessments were extracted from this meta-analysis on the primary
outcomes of the included studies
Risk of bias
Item Authors’ judgement Description
Method for selecting cases to adjudicate? No All suspect events adjudicated were identi-
fied by onsite assessor who was blinded to
allocated treatment
HOPE-2 2006
Methods RCT comparing folic acid plus vitamin B versus placebo to prevent cardiovascular events
in high-risk patients
Data 5522 patients randomised (2758/2764,) respectively in each treatment group)
Comparisons Onsite assessment (local investigator blinded) versus assessment by an AC blinded to
allocated treatment
Outcomes The outcome selected was myocardial infarction, stroke or cardiovascular death
Notes The study was identified because it was included in a pooled analysis of 10 RCTs (Pogue
2009). Data related to the number of events in each treatment group resulting from
onsite-assessor and AC assessments were extracted from this meta-analysis on the primary
outcomes of the included studies
Risk of bias
Item Authors’ judgement Description
Method for selecting cases to adjudicate? No All suspect events adjudicated were identi-
fied by onsite assessor who was blinded to
allocated treatment
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IMPACT-II 1997
Methods RCT comparing eptifibatide versus placebo to prevent cardiovascular events in high-risk
patients
Data 4010 patients randomised (2682/1328, respectively in each treatment group)
Comparisons Onsite assessment (local investigator blinded) versus assessment by an AC blinded to
allocated treatment
Outcomes The outcome selected was a 30-day composite of myocardial infarction, coronary stent
implantation, percutaneous revascularisation or death. This was the study’s primary out-
come
Notes The study was identified because it was include in a review of six RCTs (Granger 2008)
. Data related to the number of events in each treatment group resulting from onsite-
assessor and AC assessments were extracted from this review
Risk of bias
Item Authors’ judgement Description
Method for selecting cases to adjudicate? No All suspect events adjudicated were identi-
fied by onsite assessor who was blinded to
allocated treatment
Kirwan 2007
Methods RCT investigating the effect of the calcium antagonist nifedipine versus placebo on long-
term outcome in patients with stable angina pectoris
Data 7797 patients were randomly allocated study drug with 7665 patients included in inten-
tion-to-treat analyses (3825/3840, respectively in nifedipine and placebo group)
Comparisons Onsite assessment (local investigator blinded) versus assessment by an AC blinded to
allocated treatment
Outcomes The outcome selected was a composite outcome of acute myocardial infarction, refractory
angina, stroke or death. This was the study’s primary outcome
Notes
Risk of bias
Item Authors’ judgement Description
Method for selecting cases to adjudicate? No All suspect events adjudicated were identi-
fied by onsite assessor who was blinded to
allocated treatment
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McMurray 2006
Methods RCT comparing the effect of valsartanmonotherapy versus valsartan plus captopril versus
captopril monotherapy on atherosclerotic events in patients who had acute myocardial
infarction
Data 14,703 patients included in the intention-to-treat analysis of the study (4909/4885/4909,
respectively in each treatment group)
Comparisons Onsite assessment (local investigator blinded) versus assessment by an AC blinded to
allocated treatment
Outcomes The outcome selected was fatal myocardial infarction. The study’s primary outcome was
death from any cause
Notes
Risk of bias
Item Authors’ judgement Description
Method for selecting cases to adjudicate? No Specific cause of all deaths classified by on-
site assessor were adjudicated
Moss 2012
Methods RCT comparing high-rate and delayed therapy versus conventional therapy (implantable
cardioverter-defibrillator) in arrhythmias (ischaemic or non ischaemic heart disease)
Data 1500 patients were randomised (986/514, respectively in each treatment group)
Comparisons Onsite assessment (unblinded local investigator) versus assessment by a device-interroga-
tion committee (blinding status not reported) reviewing suspected events by algorithm of
implanted devices (i.e., all device interrogations with use of electronic media downloaded
from device interrogations at the enrolling centres)
Outcomes The outcome selected was the first occurrence of inappropriate therapy.This was the
study’s prespecified primary outcome
Notes
Risk of bias
Item Authors’ judgement Description
Method for selecting cases to adjudicate? No Events identified as suspected by an algo-
rithm of the implanted devices were re-
viewed independently to the onsite assessor
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Ninomiya 2009
Methods RCT comparing perindopril plus indapamide versus placebo in cerebrovascular disease
Data 6105 patients were randomised (3051/3054, respectively in each treatment group)
Comparisons Onsite assessment (local investigator blinded) versus assessment by an AC blinded to
allocated treatment
Outcomes The outcome selected was total stroke, which was the study’s primary outcome
Notes
Risk of bias
Item Authors’ judgement Description
Method for selecting cases to adjudicate? No Specific cause of all deaths and suspected
events identified by onsite assessor who was
blinded to allocated treatment were adjudi-
cated
Näslund 1999
Methods RCT comparing inogatran versus heparin in unstable coronary disease
Data 1209 patients were randomised (904/305, respectively in each treatment group)
Comparisons Onsite assessment (local investigator blinded) versus assessment by an AC (blinding status
not reported)
Outcomes The outcome selected was death, myocardial infarction (reinfarction), refractory angina
or recurrent angina.The study’s primary outcome was a composite of these events at 7
days
Notes
Risk of bias
Item Authors’ judgement Description
Method for selecting cases to adjudicate? No All suspect events adjudicated were identi-
fied by onsite assessor who was blinded to
allocated treatment
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O’ Connor 2005
Methods RCT comparing bucindolol versus placebo in patients who had moderate to severe heart
failure
Data 2708 patients were analysed (1354/1354, respectively in each group)
Comparisons Onsite assessment (local investigator blinded) versus assessment by an AC blinded to
allocated treatment
Outcomes The outcome selected was non fatal myocardial infarction. The study’s primary outcome
was total mortality
Notes
Risk of bias
Item Authors’ judgement Description
Method for selecting cases to adjudicate? No All suspect events adjudicated were identi-
fied by onsite assessor who was blinded to
allocated treatment
OASIS-1 1997
Methods RCT comparing the effects of two doses of recombinant hirudin versus heparin in patients
with acute myocardial ischaemia without ST elevation
Data 909 patients randomised (538/371 respectively in each treatment group)
Comparisons Onsite assessment (local investigator blinded) versus assessment by an AC not blinded to
allocated treatment
Outcomes The outcome selected was myocardial infarction, angina at 7 days or cardiovascular death
Notes The study was identified because it was included in a pooled analysis of 10 RCTs (Pogue
2009). Data related to the number of events in each treatment group resulting from
onsite-assessor and AC assessments were extracted from this meta-analysis on the primary
outcomes of the included studies
Risk of bias
Item Authors’ judgement Description
Method for selecting cases to adjudicate? No All suspect events adjudicated were identi-
fied by onsite assessor who was blinded to
allocated treatment
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OASIS-2 1999
Methods RCT comparing the effects of recombinant hirudin (lepirudin) versus heparin on death,
myocardial infarction, refractory angina, and revascularisation procedures in patients with
acute myocardial ischaemia without ST elevation
Data 10,141 patients randomised (5058/5083, respectively in each treatment group)
Comparisons Onsite assessment (local investigator blinded) versus assessment by an AC blinded to
allocated treatment
Outcomes The outcome selected was myocardial infarction at 7 days or cardiovascular death
Notes The study was identified because it was included in a pooled analysis of 10 RCTs (Pogue
2009). Data related to the number of events in each treatment group resulting from
onsite-assessor and AC assessments were extracted from this meta-analysis on the primary
outcomes of the included studies
Risk of bias
Item Authors’ judgement Description
Method for selecting cases to adjudicate? No All suspect events adjudicated were identi-
fied by onsite assessor who was blinded to
allocated treatment
OASIS-5 2006
Methods RCT comparing fondaparinux versus enoxaparin in acute coronary syndromes
Data 20,078 patients randomised (10,057/10,021), respectively in each treatment group)
Comparisons Onsite assessment (local investigator blinded) versus assessment by an AC blinded to
allocated treatment
Outcomes The outcome selected was refractory ischaemia or myocardial infarction at 9 days or death
Notes The study was identified because it was included in a pooled analysis of 10 RCTs (Pogue
2009). Data related to the number of events in each treatment group resulting from
onsite-assessor and AC assessments were extracted from this meta-analysis on the primary
outcomes of the included studies
Risk of bias
Item Authors’ judgement Description
Method for selecting cases to adjudicate? No All suspect events adjudicated were identi-
fied by onsite assessor who was blinded to
allocated treatment
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OASIS-6 2006
Methods RCT analysing the effects of fondaparinux, a factor Xa inhibitor, versus usual care on
mortality and reinfarction in patients with acute ST-segment elevation myocardial infarc-
tion
Data 12,092 patients randomised (6056/6036, respectively in each treatment group)
Comparisons Onsite assessment (local investigator blinded) versus assessment by an AC blinded to
allocated treatment
Outcomes The outcome selected was reinfarction at 30 days or death.
Notes The study was identified because it was included in a pooled analysis of 10 RCTs (Pogue
2009). Data related to the number of events in each treatment group resulting from
onsite-assessor and AC assessments were extracted from this meta-analysis on the primary
outcomes of the included studies
Risk of bias
Item Authors’ judgement Description
Method for selecting cases to adjudicate? No All suspect events adjudicated were identi-
fied by onsite assessor who was blinded to
allocated treatment
OPPORTUNITY 2011
Methods RCT comparing human growth hormone versus placebo in haemodialysis patients
Data 712 patients were randomised and 695 patients who received at least one dose of trial
medication (346/349, respectively in each treatment group) were considered in the full
analysis set
Comparisons Onsite assessment (local investigator blinded) versus assessment by an AC blinded to
allocated treatment
Outcomes The outcome selected was any cardiovascular event and death of any cause. The study’s
primary outcome was time to all-cause death
Notes Data related to the number of events in each treatment group resulting from onsite-
assessment were obtained directly from the study authors
Risk of bias
Item Authors’ judgement Description
Method for selecting cases to adjudicate? No All suspect events adjudicated were identi-
fied by onsite assessor who was blinded to
allocated treatment
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PARAGON-B 2002
Methods RCT comparing lamifiban versus placebo in patients with acute coronary syndrome
Data Of 5225 patients enrolled, 5163were analysed (2568/2595, respectively in each treatment
group)
Comparisons Onsite assessment (local investigator blinded) versus assessment by an AC blinded to
allocated treatment
Outcomes The primary selected was a composite outcome myocardial infarction, ischaemia or death
at 30 days. This was the study’s primary outcome
Notes
Risk of bias
Item Authors’ judgement Description
Method for selecting cases to adjudicate? No All suspect events adjudicated were identi-
fied through a computer algorithm
Prince 2006
Methods RCT comparing calcium carbonate versus placebo to prevent osteoporotic fractures
Data 1460 patients were randomised (730/730 respectively in each treatment group)
Comparisons Blinded patients self-reported outcomes versus assessment by an AC (blinding not re-
ported)
Outcomes The outcome selected was myocardial infarction. The study’s primary outcome included
clinical incident osteoporotic fractures, vertebral deformity, and adverse events ascertained
in 5 years
Notes The study was identified because it was included in a review of 2 RCTs (Lewis 2012)
. Data related to the number of events in each treatment group resulting from onsite-
assessor and AC assessments were extracted from this review
Risk of bias
Item Authors’ judgement Description
Method for selecting cases to adjudicate? Unclear The method used to select cases to adjudi-
cate was not reported
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PURSUIT 2001
Methods RCT comparing eptifibatide versus placebo in patients with acute coronary syndromes
Data 10,948 patients were randomised. Data were presented in detail for the primary com-
parison groups, those assigned to receive high-dose eptifibatide or placebo (4722/4739,
respectively in each treatment group); 1487 patients were allocated to the low-dose epti-
fibatide group
Comparisons Onsite assessment (local investigator blinded) versus assessment by an AC blinded to
allocated treatment
Outcomes The outcome selected was a composite of death or post-enrolment myocardial infarction
(or reinfarction if patients had a myocardial infarction at enrolment) by 30 days. This
was the study’s primary outcome
Notes
Risk of bias
Item Authors’ judgement Description
Method for selecting cases to adjudicate? No All suspect events adjudicated were identi-
fied through a computer algorithm
RECORD 2009
Methods RCT comparing rosiglitazone versus metformin plus sulphonylurea in patients with type
2 diabetes
Data 4447 patients were randomised (2220/2227, respectively in each treatment group)
Comparisons Onsite assessment (local investigator non blinded) versus assessment by an AC blinded
to allocated treatment
Outcomes The outcome selected was myocardial infarction. The study’s primary outcome was car-
diovascular hospitalisation or cardiovascular death.
Notes The study was identified because it was included in a review (Serebruany 2012). Data
related to the number of events in each treatment group resulting from onsite-assessor
and AC assessments were extracted from this review
Risk of bias
Item Authors’ judgement Description
Method for selecting cases to adjudicate? Yes All suspect events adjudicated were identi-
fied by onsite assessor who was blinded to
allocated treatment
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Schulman 2009
Methods RCT comparing dabigatran versus warfarin in patients with acute venous thromboem-
bolism
Data 2564 patients were randomised (1274/1265, respectively in each treatment group)
Comparisons Onsite assessment (local investigator blinded) versus assessment by an AC blinded to
allocated treatment
Outcomes The primary selectedwas a composite outcome of symptomatic venous thromboembolism
or related death. This was the study’s primary outcome
Notes
Risk of bias
Item Authors’ judgement Description
Method for selecting cases to adjudicate? No All suspect events adjudicated were identi-
fied by onsite assessor who was blinded to
allocated treatment
Shumaker 2003
Methods RCT comparing oestrogen plus progestin versus placebo in post-menopausal women
Data 4532 patients were randomised (2229/2303, respectively in each treatment group)
Comparisons Onsite assessment (local investigator blinded) versus assessment by an AC blinded to
allocated treatment
Outcomes The outcome selected was incidence of dementia.This was the study’s primary outcome
Notes
Risk of bias
Item Authors’ judgement Description
Method for selecting cases to adjudicate? No All suspect events adjudicated were identi-
fied by onsite assessor who was blinded to
treatment allocation
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Shumaker 2004
Methods RCT comparing oestrogen alone versus placebo in post-menopausal women
Data 2947 patients were randomised (1464/1483, respectively in each treatment group)
Comparisons Onsite assessment (local investigator blinded) versus assessment by an AC blinded to
allocated treatment
Outcomes The outcome selected was probable dementia.This was the study’s primary outcome
Notes
Risk of bias
Item Authors’ judgement Description
Method for selecting cases to adjudicate? No All suspect events adjudicated were identi-
fied by onsite assessor who was blinded to
allocated treatment
Thomas 2010
Methods RCT comparing sertindole versus risperidone in patients with schizophrenia
Data 9858 patients were randomised (4930/4928, respectively in each treatment group)
Comparisons Onsite assessment (non blinded local investigator) versus assessment by an AC blinded
to allocated treatment
Outcomes The outcome selected was fatal suicide. The study’s primary outcome was all-cause mor-
tality
Notes
Risk of bias
Item Authors’ judgement Description
Method for selecting cases to adjudicate? No All deaths were adjudicated for a specific
cause of death.
Topol 1993
Methods RCT comparing atherectomy versus angiography in patients with coronary artery disease
Data 1012 patients were randomised (512/500, respectively in each treatment group)
Comparisons Onsite assessment (blinded local investigator) versus assessment by an AC blinded to
allocated treatment
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Topol 1993 (Continued)
Outcomes The outcome selected was myocardial infarction. The study’s primary outcome was an-
giographic restenosis
Notes
Risk of bias
Item Authors’ judgement Description
Method for selecting cases to adjudicate? No All patients randomised were adjudicated.
Verhamme 2013
Methods RCT comparing TB-402 versus rivaroxaban for the prevention of venous thromboem-
bolism after total hip replacement
Data 632 patients were randomised (423/209, respectively in each treatment group)
Comparisons Onsite assessment (blinded local investigator) versus assessment by an AC blinded to
allocated treatment
Outcomes The outcome selected was total venous thromboembolism. This was study’s primary
outcome
Notes Data related to the number of events in each treatment group resulting from onsite-
assessment were obtained directly from the study authors
Risk of bias
Item Authors’ judgement Description
Method for selecting cases to adjudicate? No All suspect events adjudicated were identi-
fied by onsite assessor who was blinded to
allocated treatment
Wallantin 2009
Methods RCT comparing ticagrelor versus clopidogrel in patients with acute coronary syndromes
Data 18,624 patients were randomised (9333/9291, respectively in each treatment group)
Comparisons Onsite assessment (blinded local investigator) versus assessment by an AC blinded to
allocated treatment
Outcomes The outcome selected was myocardial infarction. The study’s primary outcome was the
time to the first occurrence of composite of death from vascular causes, myocardial in-
farction, or stroke
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Wallantin 2009 (Continued)
Notes The study was identified because it was included in a review (Serebruany 2012). Data
related to the number of events in each treatment group resulting from onsite-assessor
and AC assessments were extracted from this review
Risk of bias
Item Authors’ judgement Description
Method for selecting cases to adjudicate? No All suspect events adjudicated were identi-
fied by onsite assessor who was blinded to
allocated treatment
WAVE 2007
Methods RCT comparing aspirin plus clopidogrel versus clopidogrel alone in atherosclerotic pe-
ripheral arterial disease
Data 2161 patients were randomised (1080/1081, respectively in each treatment group)
Comparisons Onsite assessment (non blinded local investigator) versus assessment by an AC blinded
to allocated treatment
Outcomes The primary outcome selected was a composite outcome of myocardial infarction, stroke,
or death from cardiovascular causes
Notes The study was identified because it was included in a pooled analysis of 10 RCTs (Pogue
2009). Data related to the number of events in each treatment group resulting from
onsite-assessor and AC assessments were extracted from this meta-analysis on the primary
outcomes of the included studies
Risk of bias
Item Authors’ judgement Description
Method for selecting cases to adjudicate? Yes All suspect events adjudicated were identi-
fied by onsite assessor who was not blinded
to allocated treatment
Winston 2012
Methods RCT comparing the efficacy and safety of prophylactic oral maribavir versus oral gan-
ciclovir for prevention of cytomegalovirus disease in cytomegalovirus-seronegative liver
transplant recipients with CMV-seropositive donors
Data 307 patients were randomised (147/156, respectively in each group). Four patients never
received the study drug
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Winston 2012 (Continued)
Comparisons Onsite assessment (local investigator blinded) versus assessment by an AC (blinding status
not reported)
Outcomes The selected was the incidence of cytomegalovirus disease. This was the study’s primary
outcome
Notes
Risk of bias
Item Authors’ judgement Description
Method for selecting cases to adjudicate? Unclear The method used to select cases to adjudi-
cate was not reported
Wiviott 2007
Methods RCT comparing prasugrel versus clopidogrel in patients with acute coronary syndromes
Data 13,608 patients were randomised (6813/6795, respectively in each treatment group)
Comparisons Onsite assessment (blinded local investigator) versus assessment by an AC blinded to
allocated treatment
Outcomes The outcome selected was myocardial infarction. The study’s primary outcome was death
from cardiovascular causes, non fatal myocardial infarction, or non fatal stroke
Notes The study was identified because it was included in a review (Serebruany 2012). Data
related to the number of events in each treatment group resulting from onsite-assessor
and AC assessments were extracted from this review
Risk of bias
Item Authors’ judgement Description
Method for selecting cases to adjudicate? No All suspect events adjudicated were identi-
fied by onsite assessor who was blinded to
allocated treatment
AC: adjudication committee
RCT: randomised controlled trial
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Arnold 2013 The classification of events (bleed severity) by the onsite assessment and AC was not provided for each treatment
group
Epstein 1999 The classification of cause of death (in ventricular fibrillation or sustained ventricular tachycardia) by the onsite
assessment and AC was not provided for each treatment group
Heagerty 2002 The number of critical events (major cardiovascular outcomes) in each treatment group resulting from onsite
assessment and AC classification was not provided
Kestle 1999 The number of clinical events (shunt failures) in each treatment group resulting from onsite assessment and
AC classifications was not provided. Only the overall agreement between the AC and the onsite assessment was
available
Mahaffey 2011 The classification of events (congestive heart failure and cardiogenic shock) by the onsite assessment and the
AC was not provided for each treatment group. The study only reported the agreement rate between the onsite
assessors and the AC
McGarvey 2007 The ascertainment of cause-specific mortality (in obstructive pulmonary disease) by the onsite assessment and AC
was not provided for each treatment group
McGarvey 2012 The classification of cause-specific mortality (in chronic obstructive pulmonary disease) by the onsite assessment
and AC was not provided for each treatment group
O’Connor 2011 The classification of cause-specific mortality (in advanced heart failure) by the onsite assessment and AC was not
provided for each treatment group
Petersen 2006 The classification of cause of death (in sinus node disfunction) by the onsite assessment and AC was not provided
for each treatment group
Slee 2010 The number of events related to the classification of cause of death (cardiovascular or non cardiovascular) by the
onsite assessment and AC was not provided for each treatment group
Vejlstrup 2003 The classification of events (reinfarction and strokes) by the onsite assessment and AC was not provided for each
treatment group
AC: adjudication committee
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D A T A A N D A N A L Y S E S
This review has no analyses.
A D D I T I O N A L T A B L E S
Table 1. General characteristics
Characteristics No. (%)
Type of journal
Specialty journal 16 (34.0)
General medical journal 31 (66.0)
Medical specialty
Cardiovascular system 39 (83.0)
Neurology/psychiatry 4 (8.5)
Orthopedics/ rheumatology 2 (4.3)
Gastroenterology 1 (2.1)
Oncology 1 (2.1)
Study design
Parallel groups 47 (100.0)
Non-inferiority/equivalence trial 11 (23.4)
Multicentre studies 42 (89.4)
Sample size (median [Q1-Q3]) 3,449 [1506 to 10,000]
Funding source
Private 30 (63.8)
Mixed 14 (29.8)
Public 2 (4.3)
Unclear 1 (2.1)
Experimental treatment
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Table 1. General characteristics (Continued)
Drug 43 (91.5)
Surgery and procedure 3 (6.4)
Both 1 (2.1)
Comparator
Active treatment 12 (25.5)
Placebo 22 (46.8)
Usual care 13 (27.7)
Risk of bias regarding treatment effect in selected RCTs
Random allocation sequence adequately generated 34 (72.3)
Random allocation sequence adequately concealed 26 (55.3)
Patients blinded 36 (76.6)
Care provider blinded 34 (72.3)
Onsite assessor blinded 35 (74.5)
Missing data < 10% of randomised population 39 (83.0)
Outcome selected
Efficacy 41 (87.2)
Safety 6 (12.8)
Primary outcome of the RCT 39 (83.0)
Composite outcome 32 (68.1)
Subjectivity of the outcome selected
Subjective 35 (74.5)
composite 12 (25.5)
Q1, Q3: quartile 1, quartile 3
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Table 2. Functioning of the adjudication committee (AC) in 47 RCTs included in the meta-analysis
Characteristics No. (%)
Members of the AC independent
Yes 26 (55.3)
Not reported 21 (44.7)
Training or education of AC members
Yes 23 (48.9)
Not reported 24 (51.1)
AC blinded to treatment assignment
Yes 40 (85.1)
Not reported 7 (14.9)
AC blinded to onsite outcome assessment
Yes 5 (10.6)
No 2 (4.3)
Not reported 40 (85.1)
Information provided to the AC
Standard case report forms 26 (55.3)
All medical files/some elements 7 (14.9)
Not reported 14 (29.8)
Methods used to select cases submitted to the AC for assess-
ment
Suspected events identified by onsite assessor 37 (78.7)
Computer algorithm used to identify suspected events 3 (6.4)
All patients adjudicated 1 (2.1)
All deaths adjudicated 3 (6.4)
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Table 2. Functioning of the adjudication committee (AC) in 47 RCTs included in the meta-analysis (Continued)
Patient self-reported events 2 (4.3)
Not reported/unclear 2 (4.3)
Table 3. Interaction between ratio of odds ratio (ROR) and blinding status of onsite assessors, ACs and method used to select
cases submitted to ACs
Subgroup No. of trials ROR [95% CI] I² (%) P value for interaction
AC blinded
AC with blinding status
not reported
40
7
1.00 [0.96 to 1.04]
1.04 [0.92 to 1.18]
0 0.36
Onsite assessor blinded
Onsite assessor not
blinded
35
12
1.00 [0.96 to 1.04]
1.08 [0.94 to 1.23]
0
4
0.07
Onsite assessor blinded
Onsite
assessor not blinded and
events submitted to ACs
were identified indepen-
dent of the onsite asses-
sor assessment
Onsite
assessor not blinded and
events submitted to AC
were identified by onsite
assessor
35
2
10
1.00 [0.96 to 1.04]
0.76 [0.48 to 1.21]
1.11 [0.96 to 1.27]
0 0.03
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